Cytokinetics (CYTK) Reiterated at Overweight by Cantor Fitzgerald
September 11, 2026 7:26 AM
Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating on Cytokinetics (NASDAQ: CYTK).The analyst commented, "Management reiterated its expectation for ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
